









Markets
/
Stocks
/
nasdaq-rgnx
/

Regenxbio Inc

RGNX

7.760USD

-0.500-6.05%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

196.72MMarket Cap

LossP/E TTM



Regenxbio Inc

7.760

-0.500-6.05%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Regenxbio Inc

Currency: USD Updated: 2026-03-27

Key Insights

Regenxbio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 105 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 29.67.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Regenxbio Inc's Score

Industry at a Glance

Industry Ranking

105 / 391

Overall Ranking

220 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Regenxbio Inc Highlights

StrengthsRisks

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 88.87% year-on-year.

Overvalued

The company’s latest PE is -2.06, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 42.94M shares, decreasing 12.69% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 130.50K shares of this stock.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

29.667

Target Price

+259.16%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Regenxbio Inc is 5.80, ranking 317 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 30.34M, representing a year-over-year increase of 43.00%, while its net profit experienced a year-over-year increase of 31.19%.

Score

Industry at a Glance

Previous score

5.80

Change



Financials

4.10

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.54

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.76

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.43

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.17

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Regenxbio Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Regenxbio Inc is 6.52, ranking 256 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.06, which is -37.48% below the recent high of -1.29 and -123.69% above the recent low of -4.62.

Score

Industry at a Glance

Previous score

6.52

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 105/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Regenxbio Inc is 8.46, ranking 120 out of 391 in the Biotechnology & Medical Research industry. The average price target is 34.00, with a high of 52.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

8.46

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Buy

Current Rating

29.667

Target Price

+259.16%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Regenxbio Inc

RGNX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Regenxbio Inc is 6.13, ranking 270 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 9.78 and the support level at 6.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.42

Change

-0.29

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.006

Neutral

RSI(14)

39.425

Neutral

STOCH(KDJ)(9,3,3)

20.076

Neutral

ATR(14)

0.582

Low Volatility

CCI(14)

-102.148

Sell

Williams %R

98.366

Oversold

TRIX(12,20)

-0.573

Sell

StochRSI(14)

22.409

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

8.126

Sell

MA10

8.280

Sell

MA20

8.727

Sell

MA50

9.873

Sell

MA100

11.474

Sell

MA200

10.516

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Regenxbio Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.82%, representing a quarter-over-quarter decrease of 2.86%. The largest institutional shareholder is The Vanguard, holding a total of 3.37M shares, representing 6.54% of shares outstanding, with 5.58% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Redmile Group, LLC

4.69M

-1.72%

BlackRock Institutional Trust Company, N.A.

4.16M

-2.56%

The Vanguard Group, Inc.

Star Investors

3.34M

-2.43%

Fox (Allan Mark)

2.90M

+0.27%

JP Morgan Asset Management

2.61M

-12.57%

State Street Investment Management (US)

1.98M

+7.66%

Morgan Stanley & Co. LLC

1.45M

+94.00%

Goldman Sachs & Company, Inc.

1.62M

+0.96%

AQR Capital Management, LLC

1.29M

+38.64%

Integral Health Asset Management, LLC

1.10M

+57.14%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Regenxbio Inc is 4.42, ranking 87 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.14. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.